USPTO serial 98641763
CLARITY
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- MEIER, SHARON A
- Law office
- TMO LAW OFFICE 112
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CLARITY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Janet W. Cho
Janet W. Cho Williams Mullen200 South 10th Street, Suite 1600c/o IP DocketingRichmond, VA 23219Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Radioactive substances for scientific and commercial purposes, namely, radioactive elements for scientific purposes; radioactive elements and isotopes for industrial, scientific and research purposes; radioactive preparations for commercial purposes, namely nuclides and radionuclides, for use in radiographic techniques; radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemical products for radioactive labelling; radiodiagnostic in-vivo agent used for scientific purposes, namely, in-vivo diagnostic agent used for detection and monitoring of carcinogenesis and anti-carcinogenic therapy; radiochemical products for scientific purposes, namely, chemical products for biotechnological product development; radioactive materials for laboratory purposes, namely, radioactive elements, nuclides and radionuclides; radioactive materials for scientific purposes, namely, radioactive elements, nuclides and radionuclides | ACTIVE | — |
| 005 | Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; radiopharmaceutical preparations for the treatment and diagnosis of cancers; radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio therapeutic preparations, namely, radio-isotope markers for therapeutic or diagnostic use; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes, namely, radio-isotope markers for therapeutic or diagnostic use; diagnostic and therapeutic radioisotopes and radiochemical preparations for medical purposes, namely, for the treatment of cancers; radiopharmaceutical preparations and substances for endoradionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy, namely diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic radiopharmaceutical preparations and substances for positron emission tomography; diagnostic radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; pharmaceutical preparations in the field of oncology, namely, theranostics drugs for use in the treatment of cancer; pharmaceutical preparations in the field of precision oncology, namely, theranostics drugs for use in the treatment of cancer; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceutical preparations containing radioisotopes for treatment and diagnosis of tumors; target radiopharmaceutical pharmaceuticals containing a target molecule for the treatment of cancers; pharmaceutical preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceutical preparations for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumors, blood-borne tumors, leukemia and melanoma; radiopharmaceutical preparations containing radioisotopes with short half-lives for diagnostic applications; chemical preparations in the nature of radiopharmaceuticals for diagnostic uses; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceutical preparations containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radio-isotope markers, isotopes, preparations and reagents for medical purposes for use in radioactive labelling of cancer cells; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; positron emission tomography tracers for medical use, namely, radioactive isotopes used to label cancer cells; positron emission tomography tracers prepared for ingestion or injection into humans and animals, namely, radioactive isotopes used to label cancer cells; preparations for use in molecular imaging for medical use, namely, radioactive isotopes for in vivo imaging; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes, namely, radio-isotope markers; diagnostic radiopharmaceutical preparations and radio-isotope markers for therapeutic purposes; pharmaceutical solutions for radioactive labelling; diagnostic imaging agents for magnetic resonance imaging | ACTIVE | — |
| 010 | Radiotherapy apparatus and instruments; implantable radioactive sources of radiation, namely, implantable radiation therapy devices consisting of radioactive seeds with or without a bioabsorbable carrier assembly; insulated containers especially adapted for temperature sensitive products for medical use, namely, insulated containers especially designed for transporting and holding radiopharmaceuticals; radiation therapy equipment; radioisotope therapy apparatus for medical purposes; radio-oncological irradiation apparatus for medical purposes; radio-oncological irradiation instruments for medical purposes; linear accelerator for medical purposes in radiotherapy; apparatus and instruments for radioisotopic therapy; radiation therapy instruments for medical purposes; medical devices for use in treating or diagnosing cancers including via radiotherapy; cancer irradiation apparatus for medical purposes; cancer irradiation instruments for medical purposes; pharmaceutical instruments, namely, radiological apparatus for medical purposes for the treatment of cancer and diseases associated with cellular proliferation; medical apparatus for administering radiopharmaceutical diagnostic products; parts and fittings for the aforesaid goods | ACTIVE | — |
| 035 | Wholesale services featuring pharmaceuticals in the nature of radiopharmaceutical preparations for the treatment and diagnosis of cancers; import-exports agencies in the field of pharmaceuticals in the nature of radiopharmaceutical preparations for the treatment and diagnosis of cancers; promotion and advertising of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, bloodborne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; marketing of products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; business intermediary services for the sale and purchase of goods and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; providing an on-line commercial information directory for products and services for the treatment of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma, in the nature of radiopharmaceutical preparations; providing information, consultancy and advisory services in relation to the aforementioned services | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; custom manufacture of radiopharmaceuticals; custom manufacture of radiopharmaceuticals for the treatment, imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; providing information, consultancy and advisory services in relation to the aforementioned services | ACTIVE | — |
| 042 | Pharmaceutical, medicinal, veterinary and therapeutic research and development in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research in the nature of conducting clinical trials for others in relation to radiopharmaceuticals for use in the imaging, diagnosis, treatment and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumours, blood-borne tumours, leukemia and melanoma; scientific research and development in the field of radiopharmaceuticals and radioprotectors; scientific research and development in the field of theranostics; scientific research and development in the field of radioisotopes suitable for diagnostic and therapeutic medical use; scientific and technological services, namely, scientific research, analysis, testing, and research on radiopharmaceuticals for the diagnosis, therapy and treatment of diseases; engineering services in the field of radiopharmaceuticals and radioisotopes suitable for diagnostic and therapeutic and medical use; scientific research and development of radioisotopes suitable for radiopharmaceuticals; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for radiopharmaceuticals; scientific research and development and engineering services in the field of radioisotopes, radioisotope generators, and linkers suitable for radiopharmaceuticals; scientific research and development in the isolation and capture of radioisotopes suitable for radiopharmaceuticals; scientific research in the nature of conducting clinical trials for others, namely, conducting phase clinical trials with target radiopharmaceuticals; medical research services relating to the development of radiotherapeutics and precision oncology; research, development and testing services relating to radiopharmaceuticals; radio labelling scientific research, namely, labelling of both small molecules and biologics; providing information, advisory and consultancy services in relation to the aforementioned services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Clarity Pharmaceuticals Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named CLARITY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 21, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 21, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 21, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 7, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 7, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 7, 2026 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jul 29, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 29, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 29, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 23, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 15, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 15, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 15, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 4, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 4, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 4, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 9, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 11, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 11, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 30, 2025 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jan 30, 2025 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jan 30, 2025 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Jan 30, 2025 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Dec 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 10, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 10, 2024 | NWAP | NEW APPLICATION ENTERED | — |